AEterna Zentaris Rating Increased to Buy at Zacks (AEZS)
by Noah - The Legacy
August 24, 2015 - 6:20 AM PDT
?Zacks upgraded shares of AEterna Zentaris (NASDAQ:AEZS) from a hold rating to a buy rating in a research note released on Thursday, Analyst Ratings Net reports. The brokerage currently has $0.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Shares of AEterna Zentaris (NASDAQ:AEZS) opened at 0.1011 on Thursday. The stock’s market capitalization is $18.43 million. The company has a 50-day moving average price of $0.19 and a 200-day moving average price of $0.41. AEterna Zentaris has a 52-week low of $0.10 and a 52-week high of $1.54.
AEterna Zentaris (NASDAQ:AEZS) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.06. On average, equities analysts anticipate that AEterna Zentaris will post ($0.32) earnings per share for the current year.
A number of other brokerages have also recently commented on AEZS. HC Wainwright reaffirmed a buy rating and issued a $1.25 price objective on shares of AEterna Zentaris in a research note on Saturday, May 23rd. Canaccord Genuity reissued a hold rating and set a $0.70 price target on shares of AEterna Zentaris in a research note on Tuesday, May 12th. Finally, Maxim Group reaffirmed a buy rating on shares of AEterna Zentaris in a research note on Sunday, August 16th.
Aeterna Zentaris Inc. is a Canada based biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company currently has three wholly owned direct and indirect subsidiaries, Aeterna Zentaris GmbH (NASDAQ:AEZS), Zentaris IVF GmbH, a wholly owned subsidiary of AEZS Germany, and Aeterna Zentaris, Inc. The Company’s product candidates include Macrilen (macimorelin), an orphan drug that evaluates growth hormone deficiency in adults, and zoptarelin doxorubicin, a targeted therapy for endometrial cancer and other cancers.?
To get a free copy of the research report on AEterna Zentaris (AEZS), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts" ratings for AEterna Zentaris and related companies with MarketBeat.com"s FREE daily email newsletter.
(c) 2015 The Legacy Distributed by Newstex, LLC
The views expressed in any and all content distributed by Newstex and its re-distributors (collectively, the "Newstex Authoritative Content") are solely those of the respective author(s) and not necessarily the views of Newstex or its re-distributors. Stories from such authors are provided "AS IS," with no warranties, and confer no rights. The material and information provided in Newstex Authoritative Content are for general information only and should not, in any respect, be relied on as professional advice. Newstex Authoritative Content is not "read and approved" before it is posted. Accordingly, neither Newstex nor its re-distributors make any claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained therein or linked to from such content, nor do they take responsibility for any aspect of such content. The Newstex Authoritative Content shall be construed as author-based content and commentary. Accordingly, no warranties or other guarantees are offered as to the quality of the opinions, commentary or anything else appearing in such Newstex Authoritative Content. Newstex and its re-distributors expressly reserve the right to delete stories at its and their sole discretion.
Source: Online Publications (August 24, 2015 - 6:20 AM PDT)
News by QuoteMedia www.quotemedia.com
follow me on BLUE SKY BREAKOUT
